{"title":"Association between different dimensions of the C-reactive protein-triglyceride-glucose index and future cardiovascular disease risk in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide cohort study.","authors":"Jintao Chen, Liying Yan, Lei He, Weixue Wang","doi":"10.1186/s13098-025-01882-7","DOIUrl":"10.1186/s13098-025-01882-7","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular-kidney-metabolic (CKM) syndrome highlights the complex interplay between metabolic disturbances, kidney disease, and cardiovascular conditions. In this process, inflammation and insulin resistance play pivotal roles. The C-reactive protein-triglyceride-glucose index (CTI), a novel biomarker of insulin resistance and inflammation, remains unestablished for predicting cardiovascular disease (CVD) risk in CKM syndrome stages 0-3.</p><p><strong>Methods: </strong>This study analyzed data from the China Health and Retirement Longitudinal Study. The outcome measure was self-reported CVD. The exposure measure, CTI, was calculated as: 0.412*Ln(C-reactive protein [mg/L]) + Ln[fasting triglycerides (mg/dL) * fasting glucose (mg/dL)/2]. Cumulative CTI was calculated as: (CTI 2012 + CTI 2015)/2 *Time (2015-2012). K-means clustering was used to categorize CTI fluctuations into four distinct clusters. Cox proportional hazards models were employed to examine the relationship between CTI and new-onset CVD risk in individuals across different CKM syndrome stages. The form of this relationship was further analyzed using restricted cubic splines. Additionally, the predictive ability was assessed using the receiver operating characteristic curve.</p><p><strong>Results: </strong>This study included 5111 individuals with CKM syndrome stages 0-3, with a mean age of 61.78 ± 8.68 years, of which 45.7%(2337) were male. During the follow-up period, 555 new cases of CVD were observed (10.9%). Our findings demonstrated a significant positive linear relationship between CTI and the risk of CVD in individuals with CKM syndrome stages 0-3. In model 3, each 1.0-SD increase in cumulative CTI was associated with a 21% increase in CVD risk (adjusted hazard ratio, aHR = 1.21 [95% CI: 1.10-1.33]). Similarly, each 1.0-SD increase in baseline CTI was associated with an 18% increase in CVD risk (aHR = 1.18 [95% CI: 1.07-1.30]). Additionally, Receiver operating characteristic analysis revealed that cumulative CTI had a better predictive performance for CVD risk compared to the cumulative TyG index (AUC: 0.596 vs 0.560, DeLong test p < 0.05).</p><p><strong>Conclusions: </strong>Higher CTI levels in individuals with CKM syndrome stages 0-3 are significantly associated with increased CVD risk. Longitudinal monitoring of CTI changes over time can help early identification of high CVD risk in this population, and its predictive value is significantly superior to that of the TyG index.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"299"},"PeriodicalIF":3.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Buyu Guo, Yichen Yang, Na Wang, Yue Zhang, Caihong Jiao, Li Wang, Yanan Yan, Songbo Fu
{"title":"From the perspective of dynamic changes in BMI: the relationship between BMI trajectories and dysglycemia, all-cause mortality.","authors":"Buyu Guo, Yichen Yang, Na Wang, Yue Zhang, Caihong Jiao, Li Wang, Yanan Yan, Songbo Fu","doi":"10.1186/s13098-025-01848-9","DOIUrl":"10.1186/s13098-025-01848-9","url":null,"abstract":"<p><strong>Objectives: </strong>The aim was to explore the body mass index (BMI) trajectory over dynamic time and its relationship with the dysglycemia (including Type 2 Diabetes Mellitus and prediabetes), all-cause mortality, and insulin resistance.</p><p><strong>Methods: </strong>The latent category trajectory model (LCTM) is used to identify the BMI trajectories. Logistic and Cox regression were fitted to assess the correlation between BMI trajectories/weight changes and Type 2 Diabetes Mellitus (T2DM)/prediabetes. Using linear regression to evaluate the correlation between the two and insulin resistance. Mediating role of inflammation was evaluated.</p><p><strong>Results: </strong>Four BMI trajectories were identified, including \"stable\" (74.32%), \"light increase\" (17.18%), \"rapid increase\" (2.82%), and \"increase-to-decrease\" (5.67%). Compared to stable trajectories, participants with slight increase or increase-to-decrease trajectories had higher risks of T2DM, while participats with a slight increase or rapid increase trajectory had a higher probability of developing prediabetes. Early weight changes such as decrease, increase, overweight, or obesity were associated with higher T2DM, while recent weight changes like decrease or obesity-stable only impacted T2DM prevalence, and there were no significant associations for prediabetes.</p><p><strong>Conclusion: </strong>The findings underscore the critical impact of BMI trajectories and early/recent weight changes on T2DM and mortality risk.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"298"},"PeriodicalIF":3.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Serum moesin is associated with cognitive impairment and glucose fluctuations in patients with type 2 diabetes.","authors":"Ying Meng, Jiancan Lu, Chao Shi, Hongling Zhu, Jichen Zhang","doi":"10.1186/s13098-025-01876-5","DOIUrl":"10.1186/s13098-025-01876-5","url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment is a common complication of type 2 diabetes mellitus (T2DM); however, its underlying mechanisms are unclear. This study investigated the association between serum moesin levels, cognitive impairment, and glucose fluctuations in T2DM patients.</p><p><strong>Methods: </strong>A total of 229 T2DM patients and 150 healthy controls were enrolled, and patients with T2DM were further categorized into those with mild cognitive impairment (MCI, n = 71) and without MCI (non-MCI, n = 158). An enzyme-linked immunosorbent assay (ELISA) was used to evaluate the serum levels of moesin, high-sensitivity C-reactive protein (hs-CRP), and brain-derived neurotrophic factor (BDNF) in all participants.</p><p><strong>Results: </strong>Serum moesin levels were significantly elevated in T2DM patients compared to those in healthy controls (P < 0.001) and further increased in the MCI group compared to those in the non-MCI group (P < 0.001). Receiver operating characteristic (ROC) analysis identified an optimal moesin cutoff of 113.49 ng/mL (AUC = 0.866) for distinguishing MCI from T2DM, with 76.1% sensitivity and 86.7% specificity. Correlation analysis demonstrated that moesin was positively correlated with triglyceride, LDL-C, IMT, hs-CRP, and glucose variability markers (MAGE, MBG, SD, and MODD) but negatively correlated with years of education, BDNF, time in range (TIR), and Montreal Cognitive Assessment (MoCA) scores (P < 0.05). Multivariate logistic regression identified BMI, years of education, diabetes duration, FBG, hs-CRP, BDNF, MAGE, SD, and moesin as independent predictors of MCI in T2DM (P < 0.05).</p><p><strong>Conclusions: </strong>These findings suggest that elevated serum moesin levels are associated with cognitive impairment in patients with T2DM, potentially mediated by glucose fluctuations, inflammation, and vascular dysfunction.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"301"},"PeriodicalIF":3.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai
{"title":"Systemic evaluation of the effects of monomeric GLP-1R-based agonists on MASLD and its complications.","authors":"Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai","doi":"10.1186/s13098-025-01870-x","DOIUrl":"10.1186/s13098-025-01870-x","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide, yet efficient therapeutic approaches are lacking. The advent of glucagon-like peptide-1 receptor (GLP-1R)-based multi-target agonists generated renewed optimism for MASLD. Building on preclinical and clinical data suggesting synergistic metabolic benefits, we hypothesized that combining glucose-dependent insulinotropic polypeptide receptor (GIPR) or glucagon receptor (GCGR) agonism with GLP-1R agonism would confer superior protective effects against MASLD and its complications.</p><p><strong>Methods: </strong>We identified genetic proxies of the effect of GLP-1R, GIPR, and GCGR by combining Mendelian randomization (MR), Bayesian colocalization, and linkage disequilibrium (LD) analyses. We then performed two-sample MR and colocalization analyses to estimate the causal effect of GLP-1R-based agonists on MASLD, its metabolic risk factors, and multi-organ complications.</p><p><strong>Results: </strong>The MR analyses suggested genetically proxied GLP-1R-based agonists were causally associated with a reduced risk of MASLD (GIPR/GLP-1R agonist: OR: 0.17, 95%CI: 0.05-0.52, P = 2.07 × 10<sup>- 3</sup>; GCGR/GLP-1R agonist: OR: 0.32, 95%CI: 0.20-0.52, P = 3.93 × 10<sup>- 6</sup>; GCGR/GIPR/GLP-1R agonist: OR: 0.21, 95%CI: 0.08-0.56, P = 1.98 × 10<sup>- 3</sup>), and these findings were well replicated in an independent cohort. Furthermore, these agonists also exhibited protective effects against liver cancer and cardiovascular diseases, as well as three metabolic risk factors, namely high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and insulin sensitivity index adjusted for BMI (ISI).</p><p><strong>Conclusions: </strong>We identified the causal role of GLP-1R-based agonists in reducing the risk of MASLD and its complications, probably by improving systemic metabolic disorders and partly independent of their weight-loss effect.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"300"},"PeriodicalIF":3.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rong Ouyang, Han Zhang, Xiaoqin Zhao, Renyue Hu, Yi Sun, Wei Chen, Chen Qian, Yunjuan Gu, Xinlei Wang
{"title":"Relationship between glucose response curve shape during the oral glucose tolerance test and macrovascular complications in type 2 diabetes mellitus.","authors":"Rong Ouyang, Han Zhang, Xiaoqin Zhao, Renyue Hu, Yi Sun, Wei Chen, Chen Qian, Yunjuan Gu, Xinlei Wang","doi":"10.1186/s13098-025-01867-6","DOIUrl":"10.1186/s13098-025-01867-6","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluated the predictive value of glucose response curve shape during the oral glucose tolerance test (OGTT) for macrovascular complications in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Research design and methods: </strong>A retrospective observational analysis was conducted involving 75 subjects with normal glucose tolerance (NGT) and 496 patients with T2DM, all of whom underwent a 3-hour OGTT, along with insulin and C-peptide release tests. Multivariate linear regression models assessed the cross-sectional associations between glucose response curve shapes and common carotid artery (CCA) diameter and intima-media thickness (IMT) in T2DM patients. Risk factors for carotid atherosclerosis analyzed using multivariate logistic regression.</p><p><strong>Results: </strong>Among patients with type 2 diabetes who underwent OGTT, the group with monophasic curves (n = 282) showed higher blood glucose levels, increased insulin resistance, and poorer pancreatic β-cell function compared to the multiphasic curve group (n = 214). Larger CCA diameters were independently associated with monophasic curves compared to multiphasic curves (regression coefficient: 0.134 [0.016, 0.252], P = 0.026). Increased IMT was independently associated with monophasic curves compared to multiphase curves (regression coefficient: 0.038 [0.001, 0.075], P = 0.045). Independent risk factors for carotid atherosclerosis in T2DM patients included monophasic curve (odds ratio [OR] 2.014, 95% confidence interval [CI] 1.300-3.121, P = 0.002), age (OR 1.040, 95% CI 1.020-1.059, P < 0.001), male sex (OR 2.107, 95% CI 1.364-3.256, P = 0.001), and duration of diabetes (OR 1.043, 95% CI 1.009-1.078, P = 0.012).</p><p><strong>Conclusion: </strong>The shape of the glucose response curve during OGTT was significantly linked to the risk of macrovascular complications in T2DM patients. Those with monophasic glucose curves were at an elevated risk of developing such complications.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"294"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sijia Lai, Yaohui Feng, Lu Li, Jiayu Zhao, Zhenyu Wang, Yanli Wang
{"title":"Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization.","authors":"Sijia Lai, Yaohui Feng, Lu Li, Jiayu Zhao, Zhenyu Wang, Yanli Wang","doi":"10.1186/s13098-025-01866-7","DOIUrl":"10.1186/s13098-025-01866-7","url":null,"abstract":"<p><strong>Background: </strong>Glucose-lowering glucagon-like peptide-1 receptor agonists (GLP1RAs) are widely used to treat type 2 diabetes (T2D) and obesity. However, their potential benefits in pulmonary diseases remain unclear. To address this, we used Mendelian randomization (MR) analysis to assess the causal effects of genetically proxied GLP1RAs on chronic obstructive pulmonary disease (COPD) and related conditions, including bronchitis and asthma.</p><p><strong>Methods: </strong>We selected cis-expression quantitative trait loci (cis-eQTLs) as instrumental variables to genetically proxy GLP1RAs. Summary-level data were obtained from the eQTLGen and FinnGen consortia. MR analyses were used to identify the association between genetically proxied GLP1RAs and COPD, as well as COPD-related diseases. T2D, HbA1c levels, and BMI were used as positive controls.</p><p><strong>Results: </strong>After Benjamini-Hochberg correction for multiple testing, MR analyses indicated that genetically predicted GLP1RAs were significantly associated with lower risks of COPD (OR [95% CI] = 0.838 [0.74-0.948], P = 0.013), early-onset COPD (< 65 years) (OR [95% CI] = 0.751[0.622-0.906], P = 0.01), COPD-related respiratory insufficiency (OR [95% CI] = 0.720[0.55-0.944], P = 0.024), acute bronchitis (OR [95% CI] = 0.787 [0.693-0.893], P = 0.002), asthma (OR [95% CI] = 0.872 [0.782-0.973], P = 0.023), and other symptoms and signs involving the circulatory and respiratory systems (OR [95% CI] = 0.426 [0.217-0.834], P = 0.023). No significant association was observed for later-onset COPD (≥ 65 years) (OR [95% CI] = 0.921 [0.783-1.082], P = 0.315) or chronic bronchitis risk (OR [95% CI] = 0.950 [0.889-1.016], P = 0.146).</p><p><strong>Conclusions: </strong>Genetically predicted GLP1RAs are associated with a lower risk of early-onset COPD, COPD-related respiratory insufficiency, acute bronchitis, and asthma. These findings highlight potential benefits of GLP1RAs in T2D patients with coexisting pulmonary diseases and support the need for further investigation in COPD management.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"295"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dae Young Cheon, Kyungdo Han, Ye Seul Yang, Minwoo Lee, Mi Sun Oh
{"title":"Diabetes status, duration and risk of dementia in patients with myocardial infarction.","authors":"Dae Young Cheon, Kyungdo Han, Ye Seul Yang, Minwoo Lee, Mi Sun Oh","doi":"10.1186/s13098-025-01863-w","DOIUrl":"10.1186/s13098-025-01863-w","url":null,"abstract":"<p><strong>Background: </strong>This study examines how diabetes mellitus (DM), specifically its diagnostic status and duration, influences dementia risk in individuals with a history of myocardial infarction (MI). We evaluated whether DM correlates with an increased incidence of all-cause dementia, as well as Alzheimer's disease (AD) and vascular dementia (VaD).</p><p><strong>Methods: </strong>Utilizing from the Korean National Health Insurance Database (K-NHID), this retrospective cohort study included 43,561 patients with a history of MI but no prior dementia diagnosis, tracked from 2009 to 2018. Glycemic status was categorized into normoglycemia, impaired fasting glucose (IFG), new-onset DM, and established DM of durations < 5 and ≥ 5 years. The primary outcome was all-cause dementia.</p><p><strong>Results: </strong>During the median follow-up of 7.6 years, the incidence of dementia was 10.1%. Patients with established DM (≥ 5 years) exhibited a significantly higher risk of developing all-cause dementia compared to those with normoglycemia. The findings were consistent in both AD and VaD. Subgroup analyses revealed that younger patients (< 65 years) faced an even greater risk of dementia.</p><p><strong>Conclusions: </strong>We found a significant association between the duration of DM and an elevated risk of all-cause dementia, along with AD and VaD in post-MI patients. Our findings highlight the importance of diabetes management in preserving brain health among patients with a history of myocardial infarction.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"296"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The effect of medroxyprogesterone acetate plus conjugated equine estrogens on lipoprotein(a) and apolipoprotein concentrations in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.","authors":"Rui Han, Zhen Wang, Kousalya Prabahar, Dan Wan","doi":"10.1186/s13098-025-01788-4","DOIUrl":"10.1186/s13098-025-01788-4","url":null,"abstract":"<p><strong>Objective: </strong>The influence of medroxyprogesterone acetate plus conjugated equine estrogens (MPA/CEE) on apolipoproteins and lipoprotein(a) levels has been vastly studied with inconsistent results. These inconsistencies could be attributed to several factors, such as the characteristics of the included participants and dosage and duration of intervention, among others. This study was conducted to determine the impact of MPA/CEE on the lipoprotein(a) and apolipoprotein concentrations in the postmenopausal women through a systematic review and meta-analysis of randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>A comprehensive search was conducted across multiple databases for relevant RCTs up to April 2025, and a random-effects model was used to conduct a meta-analysis, with results presented as the weighted mean difference (WMD) along with a 95% confidence interval (CI). Subgroup and sensitivity analyses were further conducted to find potential sources of heterogeneity.</p><p><strong>Results: </strong>The current meta-analysis included 27 RCTs with 37 study arms. The study results revealed an increase in Apolipoprotein A1 (WMD: 12.42 mg/dL, 95%CI: 9.31, 15.52, P < 0.001), as well as a decline in Apolipoprotein B (WMD: -6.84 mg/dL, 95%CI: -8.28, -5.39, P < 0.001) and lipoprotein(a) (WMD: -5.12 mg/dL, 95%CI: -6.58, -3.65, P < 0.001) concentrations following MPA/CEE administration in postmenopausal women.</p><p><strong>Conclusions: </strong>This meta-analysis indicates that MPA/CEE has a beneficial impact in the levels of atherogenic lipoproteins, which be correlated with a reduction in cardiovascular disease risk.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"297"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Raymond Rubianto Tjandrawinata, Isabela Caiado Caixeta Vencio, Axel Brahmantyo Maynardo Nugroho, Jonathan Hartanto, Nicolas Daniel Widjanarko, Fahrul Nurkolis
{"title":"Guardians of the sea: molecular and biochemical adaptations in sharks and whales for atherosclerosis resistance and their potential in human cardioprotection.","authors":"Raymond Rubianto Tjandrawinata, Isabela Caiado Caixeta Vencio, Axel Brahmantyo Maynardo Nugroho, Jonathan Hartanto, Nicolas Daniel Widjanarko, Fahrul Nurkolis","doi":"10.1186/s13098-025-01868-5","DOIUrl":"10.1186/s13098-025-01868-5","url":null,"abstract":"<p><p>This review explores unique molecular and biochemical adaptations in sharks and whales that confer resistance to atherosclerosis despite high lipid concentrations, unlike atherosclerosis-prone terrestrial mammals (e.g., humans, primates) and shorter-lived marine species (e.g., seals, dolphins). Central to our hypothesis is that sharks and whales evolved unique lipid quality management, specialized peptide systems, and genomic expansions beyond ubiquitous marine omega-3 polyunsaturated fatty acids (PUFAs) to prevent plaque formation. Comparative lipidomics highlights marine-specific profiles rich in anti-inflammatory omega-3 PUFAs, contributing to vascular protection and plaque prevention. Sharks demonstrate potent anti-angiogenic peptides and aminosterols (e.g., squalamine, trodusquemine) that modulate key pathways like PTP1B inhibition, thus reducing inflammation and endothelial dysfunction. Whales exhibit specialized lipid metabolites in blubber, including esterified omega-3 PUFAs, enhancing antioxidant enzyme activity and endothelial nitric oxide production, crucial for maintaining vascular health. Genomic insights further reveal expanded antioxidant gene families in whales, highlighting potential translational strategies to human cardiovascular therapies. Future therapeutic strategies must resolve challenges in ethical sourcing, bioavailability, and scalability. CLINICAL TRIAL NUMBER: Not applicable.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"293"},"PeriodicalIF":3.9,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12291266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Babi Dutta, Aparna Tripathy, P R Archana, Shobha U Kamath
{"title":"Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome.","authors":"Babi Dutta, Aparna Tripathy, P R Archana, Shobha U Kamath","doi":"10.1186/s13098-025-01837-y","DOIUrl":"10.1186/s13098-025-01837-y","url":null,"abstract":"<p><p>The consumption of a high-fat high-calorie diet with or without fructose (western or cafeteria diet) increases body mass due to calorie excess, inducing glucolipid metabolism dysfunctions culminating in development of unhealthy obesity and metabolic syndrome (MetS). Understanding the sequelae of events that translates caloric excess to the development of MetS symptoms interlinking metabolic interrelationship between organs is paramount in the development of new treatment strategies. This review aims to create a compendium of evidence from mammalian studies (rodents, humans) to elucidate the metabolic changes induced by overnutrition. This review explores gut microbiome alterations, gut barrier dysfunctions, and immune dysregulation induced by a high-fat diet that changes gut tryptophan and biliary metabolism, which, with concomitant elevations in free fatty acids and ceramides, promote insulin insensitivity. Immunometabolic alteration induce adipose tissue dysfunction, which alters the secretion of adipokines and lipid metabolites that contribute to dyslipidemia, hepatosteatosis, cardiovascular dysfunction, and endocrine disruption. This review provides insights into the mechanism underlying unhealthy adipose expansion, shedding light on some of the exosome-mediated epigenomic alterations affecting obesity or MetS pathogenesis, which may help in the future design of microRNA biomarkers. The review also highlights areas where more supportive evidence may be needed to elucidate metabolic syndrome pathogenesis.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"292"},"PeriodicalIF":3.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12281772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}